SAN FRANCISCO, March 12 /PRNewswire-FirstCall/ -- Medivation, Inc. today announced that subdomain data on the effect of Dimebon(TM) on behavioral symptoms in patients with mild-to-moderate Alzheimer's disease and the impact on caregivers will be presented for the first time at the annual meeting of the American Association for Geriatric Psychiatry (AAGP) in Orlando.
The data, from the Company's first pivotal trial of Dimebon, will be presented by Jeffrey Cummings, M.D., on Saturday, March 15, at 1:00 p.m. Eastern time during a poster session on new research topics. The poster presentation is entitled "Dimebon Stabilizes Neuropsychiatric Symptoms in Alzheimer's Disease: One-year Clinical Trial Results."
Medivation previously announced efficacy and safety results from the pivotal, 12-month, double-blind, placebo-controlled trial of Dimebon in 183 patients with mild-to-moderate Alzheimer's disease. Dimebon demonstrated statistically significant benefit versus placebo on all five efficacy endpoints at 12 months, including on the Neuropsychiatric Inventory (NPI), a measure of behavioral symptoms of Alzheimer's disease. The Dimebon presentation at the AAGP conference will include detailed results of an analysis of the 12 subdomains of the NPI, which include depression/dysphoria, irritability and apathy/indifference, among others. A confirmatory Phase 3 trial is scheduled to start in the second quarter of 2008.
"Behavioral symptoms are among the most difficult aspects of Alzheimer's disease that caregivers face," said Lynn Seely, M.D., chief medical officer of Medivation. "New treatment options are needed as current Alzheimer's disease therapies provide limited benefit in improving these symptoms."
About Medivation
Medivation, Inc. is a biopharmaceutical company with small molecule drugs in clinical development to treat three large, unmet medical needs -- Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer. The Company's strategy is to identify promising product candidates, to develop them in a rapid, cost-effective manner, and to seek development and/or commercialization partners as appropriate to complement its internal efforts. For more information, please go to http://www.medivation.com.
This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to differ significantly from those projected. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. None of the Company's product candidates has been approved for sale, significant additional animal and human testing is required in order to seek marketing approval for any of its product candidates, and Medivation cannot assure you that marketing approval can be obtained for any of its product candidates. Furthermore, as is typically the case at this stage of the regulatory review process, the FDA has not yet performed an in-depth review of Medivation's preclinical and clinical data, so its views remain subject to change. Medivation's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-KSB for the year ended December 31, 2007, include information about additional factors that could affect the Company's financial and operating results.
CONTACT: Patrick Machado, Chief Financial Officer of Medivation, Inc.,
+1-415-829-4101; or Jani Bergan of WeissComm Partners, +1-415-946-1064, for
Medivation, Inc.
Web site: http://www.medivation.com/
